SCHEMBL1643592

SCHEMBL1643592

CCC(CO)NCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
CNR1 P21554 1/20 0.56
ADRA1A P35348 1/20 0.56
KDM4E B2RXH2 1/20 0.56
ABCC3 O15438 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
DPP4 P27487 2/20 0.42
MME P08473 1/20 0.37
ACE P12821 1/20 0.37
CPA1 P15085 1/20 0.37
ACE2 Q9BYF1 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.34
PTGS2 P35354 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044031 0.88 MME (0.41) LMNATDP1CNR1ADRA1AKDM4E
SCHEMBL16267385 0.86 MME (0.39) LMNATDP1CNR1ADRA1AKDM4E
SCHEMBL4159987 0.85 LDHA (0.35) LMNATDP1CNR1ADRA1AKDM4E
SCHEMBL18558762 0.80 TDP1 (0.39) LMNATDP1CNR1ADRA1AKDM4E
SCHEMBL28072269 0.80 MME (0.36) LMNATDP1CNR1ADRA1AKDM4E
SCHEMBL3723836 0.80 MME (0.36) LMNATDP1CNR1ADRA1AKDM4E
SCHEMBL10337935 0.78 MME (0.35) LMNATDP1CNR1ADRA1AKDM4E
SCHEMBL26142063 0.78 MME (0.39) LMNATDP1CNR1ADRA1AKDM4E
Ethambutol SCHEMBL2319449 0.78 LMNA (0.71) LMNATDP1CNR1ADRA1AKDM4E
Ethambutol SCHEMBL8575513 0.77 LMNA (0.77) LMNATDP1CNR1ADRA1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295195-A1 ANTIMICROBIAL ORGANOSILANES Tipikos Pharmaceuticals, Inc. (US) 2023-09-21 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
WO-2021077119-A1 ANTIMICROBIAL ORGANOSILANES TOPIKOS PHARMACEUTICALS, INC. (US) 2021-04-22 WO disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
US-20110095103-A1 Product release system to atomize cosmetic hair and skin cleaning compositions PROCTER & GAMBLE COMPANY, THE 2011-04-28 US disclosed
EP-1896138-A1 A PRODUCT RELEASE SYSTEM TO ATOMIZE COSMETIC HAIR AND SKIN CLEANING COMPOSITIONS The Procter and Gamble Company (US) 2008-03-12 EP disclosed
WO-2007001844-A1 A PRODUCT RELEASE SYSTEM TO ATOMIZE COSMETIC HAIR AND SKIN CLEANING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295195-A1 ANTIMICROBIAL ORGANOSILANES ARG1, ACMSD, AAAS LMNA 4596/4885TDP1 2646/4885CNR1 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.